Resumen

IZQUIERDO CANO, Lissete M et al. Itolizumab humanized monoclonal antibody (anti-cd6) in patients with cd6+ lymphoproliferative disorders. Preliminary experience. Rev Cubana Hematol Inmunol Hemoter [online]. 2014, vol.30, n.3, pp. 0-0. ISSN 0864-0289.

CD6 molecule is a membrane glycoprotein considered a leukocyte differentiation antigen. Itolizumab, humanized monoclonal antibody (anti-CD6) recognizes the human CD6 molecule in malignant peripheral mononuclear cells of patients with B-cell chronic lymphocytic leukemia and in lymphocytes of cutaneous lesions in patients with cutaneous T- cell lymphoma. We describe preliminary results of 3 patients with B-cell chronic lymphocytic leukemia treated with itolizumab at a weekly dose of 0.8mg/kg/dose for 12 weeks. Product administration safety was evaluated in patients with CD6+ lymphoproliferative disorders and preliminary evidence of therapeutic effect of the drug was obtained. In 100% of the patients the onset of fever and chills associated to the first infusion were reported. No serious adverse effects were observed. All patients evaluated had at least some clinical or hematological improvement.

Palabras clave : itolizumab, humanized monoclonal antibody (anti-CD6); CD 6 + lymphoproliferative disorders; B- cell chronic lymphocytic leukemia.

        · resumen en Español     · texto en Español     · Español ( pdf )